MiniMed Group (MMED) Stock Gains +15.4% in 30 Days: Drivers Behind the Advance
Key Takeaways
- MMED shares climbed roughly 15.4% over the last 30 days, from a closing price of $16.93 on July 17, 2026, to $19.53 at the latest available close.
- The advance was supported by expanded U.S. Medicare access to the MiniMed Flex system, the start of commercial U.S. shipments with Abbott's Instinct sensor, and favorable analyst actions.
- Over the past three months, the stock is up approximately 79%, rebounding sharply from its post-IPO low near $10.65 reached in May 2026.
- Wall Street consensus remains bullish, with a Strong Buy average rating and an average price target near $21.36, though the company still reports GAAP losses.
- Key watch items include the fiscal 2027 first-quarter report scheduled for September 1, 2026, U.S. product adoption, and the timeline for Medtronic's planned distribution of its stake.
MiniMed Group (MMED) Company Overview and Market Position
MiniMed Group, Inc. is a diabetes technology company that develops, manufactures, and markets insulin delivery and glucose monitoring systems. Its portfolio includes automated insulin delivery platforms such as the MiniMed 780G and MiniMed Flex systems, continuous glucose monitors including Simplera Sync and Instinct sensors, the InPen smart insulin pen, infusion sets, and the CareLink software platform.
The company was founded in 1983, was acquired by Medtronic (MDT) in 2001, and returned to the public market as a separate Nasdaq-listed company in March 2026. Medtronic still owns roughly 90% of MiniMed shares. MiniMed serves about 650,000 people with diabetes across more than 80 countries, generates around 70% of revenue outside the United States, and derives approximately 80% of revenue from recurring CGM, consumables, and related streams. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
MiniMed Group (MMED) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MMED rose from $16.93 on July 17, 2026, to $19.53 at the latest available close, a gain of about 15.4%. The move extended a larger recovery: over the past three months, the stock has advanced roughly 79%, from $10.89 on May 19, 2026, to $19.53. That rebound followed early post-IPO pressure that took the shares to a 52-week low near $10.65 in May 2026.
The 30-day gain therefore sits within a broader uptrend rather than an isolated spike. Daily trading has remained active, and the latest session's pullback of about 3.1% reflected normal consolidation after the stock approached its upper trading range.
What Drove MMED Stock Price in the Last 30 Days
Commercial execution and improving sell-side sentiment were the main drivers of the recent advance. In late July, MiniMed announced that Medicare and Medicare Advantage beneficiaries had gained access to the MiniMed Flex system with its latest sensor portfolio, widening the U.S. reimbursement runway. Around the same time, UBS initiated coverage with a Buy rating and a $25 price target, arguing that shares had been undervalued following the post-IPO decline.
In August, BofA raised its MiniMed price target to $24 from $20 and reiterated a Buy rating, noting that Medtronic's roughly 90% ownership had likely been an overhang and that a potential window for Medtronic to exchange its stake could be approaching. MiniMed also announced that the MiniMed Flex system was commercially shipping in the United States with the Instinct sensor made by Abbott (ABT), combining its smallest app-controlled insulin pump with Abbott's compact sensor.
What Drove MMED Stock Performance Over the Last Quarter
The three-month move is primarily a post-IPO rebound story. After its March 2026 debut, MMED initially slid and bottomed near $10.65 in May before firming. The inflection came with fiscal 2026 fourth-quarter results in early June, when quarterly revenue reached $837 million, up 16% as reported and 8.7% organically, and full-year revenue surpassed $3 billion for the first time. Adjusted EBITDA rose 32% in the quarter, and management outlined roughly 10% organic growth for fiscal 2027.
Product momentum reinforced that narrative: the MiniMed Flex pump became available in the U.S. in June 2026, sensor options expanded through the Abbott collaboration, and international demand remained strong. Analyst initiations, price-target increases, and growing attention to the eventual Medtronic share distribution added further support to the recovery.
MMED Stock Forecast Drivers: What Investors Should Watch Next
The next major catalyst is MiniMed's fiscal 2027 first-quarter report, scheduled for September 1, 2026. Investors will focus on U.S. uptake of the MiniMed Flex system with Instinct, CGM attachment rates, international growth, and any updated guidance. The timing and mechanics of Medtronic's planned distribution or exchange of its remaining stake also remain central to the supply-and-demand picture for the stock.
Broader factors include Medicare and commercial reimbursement coverage, competitive pressure in automated insulin delivery, sensor and pump manufacturing execution, foreign-exchange effects, and the company's progress toward narrowing GAAP losses. Consensus estimates project a swing toward positive earnings per share in fiscal 2027, but execution risk and valuation sensitivity remain important considerations. One thing that stands out is how quickly sentiment has shifted since the post-IPO low.
Exploring AI Tools for Systematic Stock Strategies
In my research process, I often turn to Tickeron’s Trending AI Robots page. It highlights a curated selection of AI-powered trading bots from a broader marketplace that spans hundreds of bots trading thousands of tickers. Only top-performing and most relevant bots appear in this section, helping filter a large universe down to timely ideas. The bots vary by strategy, timeframe, and performance metrics, so traders can review approaches that align with different market conditions and objectives. Investors monitoring stocks such as MMED can use the page as a discovery tool for systematic, data-driven trading strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MMED in +1.96% Uptrend, advancing for three consecutive days on September 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MMED advanced for three days, in 24 of 26 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Aroon Indicator entered an Uptrend today. In 22 of 22 cases where MMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for MMED moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 3 similar instances where the indicator moved out of overbought territory. In 2 of the 3 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Momentum Indicator moved below the 0 level on September 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MMED as a result. In 3 of 5 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.
The Moving Average Convergence Divergence Histogram (MACD) for MMED turned negative on September 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 5 similar instances when the indicator turned negative. In 3 of the 5 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
MMED broke above its upper Bollinger Band on September 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.693) is normal, around the industry mean (4.961). P/E Ratio (0.000) is within average values for comparable stocks, (161.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.443). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.950) is also within normal values, averaging (56.074).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther
Advertisement